Rate of neuropathic progression in hereditary transthyretin amyloidosis with polyneuropathy and other peripheral neuropathies: a systematic review and meta-analysis
- PMID: 33579211
- PMCID: PMC7879641
- DOI: 10.1186/s12883-021-02094-y
Rate of neuropathic progression in hereditary transthyretin amyloidosis with polyneuropathy and other peripheral neuropathies: a systematic review and meta-analysis
Abstract
Background: We aimed to compare neuropathic progression rate between hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) and other peripheral neuropathies, including diabetic peripheral neuropathy (DPN) and Charcot-Marie-Tooth disease (CMT).
Methods: Literature searches identified studies reporting neuropathic progression, measured by Neuropathy Impairment Score (NIS) or NIS-Lower Limbs (NIS-LL). Our study also included unpublished data from a clinical registry of patients who were diagnosed with different peripheral neuropathies and seen at the Oregon Health & Science University (OHSU) during 2016-2020. Meta-analysis and meta-regression models examined and compared annual progression rates, calculated from extracted data, between studies of ATTRv-PN and other peripheral neuropathies.
Results: Data were synthesized from 15 studies in which NIS and/or NIS-LL total scores were assessed at least twice, with ≥12 weeks between assessments, among untreated patients with ATTRv-PN or other peripheral neuropathies. Meta-analysis models yielded that the annual progression rate in NIS total scores was significantly different from zero for studies in ATTRv-PN and CMT (11.77 and 1.41; both P < 0.001), but not DPN (- 1.96; P = 0.147). Meta-regression models showed significantly faster annual progression in studies in ATTRv-PN, which statistically exceeded that in other peripheral neuropathies by 12.45 points/year for NIS, and 6.96 for NIS-LL (both P < 0.001).
Conclusions: Peripheral nervous function deteriorates more rapidly in patients with ATTRv-PN than for other peripheral neuropathies. These findings may improve understanding of the natural history of neuropathy in ATTRv-PN, facilitate early diagnosis, and guide the development of assessment tools and therapies specifically targeting neuropathic progression in this debilitating disease.
Keywords: Hereditary transthyretin amyloidosis with polyneuropathy; Meta-analysis; Neuropathic progression; Neuropathy impairment score; Peripheral neuropathy.
Conflict of interest statement
XL, AY, NB, and JB are employees of QualityMetric, which received funding from Akcea Therapeutics for conducting this research. MVL and DB are employees of and own stock in Akcea Therapeutics. CK has received support from Acceleron, Akcea Therapeutics, Alexion, Alnylam, Biogen, Cytokinetics, CSL Behring, and Sanofi Genzyme. BV declares no conflict of interest.
Figures




Similar articles
-
The impact of inotersen on Neuropathy Impairment Score in patients with hereditary transthyretin amyloidosis with polyneuropathy.BMC Neurol. 2023 Mar 17;23(1):108. doi: 10.1186/s12883-023-03116-7. BMC Neurol. 2023. PMID: 36932361 Free PMC article. Clinical Trial.
-
Indirect treatment comparison (ITC) of the efficacy of vutrisiran and tafamidis for hereditary transthyretin-mediated amyloidosis with polyneuropathy.Expert Opin Pharmacother. 2023 May-Aug;24(10):1205-1214. doi: 10.1080/14656566.2023.2215925. Epub 2023 May 26. Expert Opin Pharmacother. 2023. PMID: 37219406
-
3-T MR neurography of lumbo-sacral plexus in hereditary transthyretin-related amyloidosis with polyneuropathy.Eur Radiol. 2022 Nov;32(11):7865-7871. doi: 10.1007/s00330-022-08748-w. Epub 2022 Apr 19. Eur Radiol. 2022. PMID: 35438324
-
The neuropathy in hereditary transthyretin amyloidosis: A narrative review.J Peripher Nerv Syst. 2021 Jun;26(2):155-159. doi: 10.1111/jns.12451. Epub 2021 May 11. J Peripher Nerv Syst. 2021. PMID: 33960565 Free PMC article. Review.
-
Development of measures of polyneuropathy impairment in hATTR amyloidosis: From NIS to mNIS + 7.J Neurol Sci. 2019 Oct 15;405:116424. doi: 10.1016/j.jns.2019.116424. Epub 2019 Aug 8. J Neurol Sci. 2019. PMID: 31445300 Review.
Cited by
-
Responder analysis for neuropathic impairment and quality-of-life assessment in patients with hereditary transthyretin amyloidosis with polyneuropathy in the NEURO-TTR study.J Neurol. 2022 Jan;269(1):323-335. doi: 10.1007/s00415-021-10635-1. Epub 2021 Jun 14. J Neurol. 2022. PMID: 34125267 Free PMC article.
-
Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update.J Neurol. 2022 Dec;269(12):6416-6427. doi: 10.1007/s00415-022-11276-8. Epub 2022 Jul 31. J Neurol. 2022. PMID: 35908242 Free PMC article. Clinical Trial.
-
Real-life experience with inotersen in hereditary transthyretin amyloidosis with late-onset phenotype: Data from an early-access program in Italy.Eur J Neurol. 2022 Jul;29(7):2148-2155. doi: 10.1111/ene.15325. Epub 2022 Mar 28. Eur J Neurol. 2022. PMID: 35289020 Free PMC article.
-
Hereditary transthyretin amyloidosis: a comprehensive review with a focus on peripheral neuropathy.Front Neurol. 2023 Oct 5;14:1242815. doi: 10.3389/fneur.2023.1242815. eCollection 2023. Front Neurol. 2023. PMID: 37869146 Free PMC article. Review.
-
Effectiveness of patisiran after switching from tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy.Eur J Neurol. 2024 Sep;31(9):e16384. doi: 10.1111/ene.16384. Epub 2024 Jul 10. Eur J Neurol. 2024. PMID: 38988097 Free PMC article.
References
Publication types
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials